Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less

Prescription Drugs Industry Research & Market Reports

  • Drug Wholesalers

    ... in the US), as well as Jointown Pharmaceutical (China), Medipal (Japan) and PHOENIX (Germany). COMPETITIVE LANDSCAPE Demand for pharmaceutical distribution is driven by the need to treat illness and disease. The profitability of individual companies ... Read More

  • Cuba Pharmaceuticals & Healthcare Q1 2019

    ... drink industry during our forecast period to 2022. However, the growth will bedistributed unevenly: we expect cereals, baked goods and meat to outperform in the food sector, while dairy and bread sales willremain modest. Similar ... Read More

  • Finland Pharmaceuticals & Healthcare Q1 2019

    ... in line with economic headwinds, structural constraints in the labour market and more limited EUinvestment. We expect the construction industry's value to total over USD25bn by 2027, dominated by the residential and non-residential buildings sector. Read More

  • Hong Kong Pharmaceuticals & Healthcare Q1 2019

    ... to average employment and income rates and thebroadening of product lines to include more affordable microinsurance products will make cover in both the life and non-life sectormore accessible to first time users and boost premium ... Read More

  • Australia Pharmaceuticals & Healthcare Q1 2019

    ... utilising cloud and edge computing, Internet of Things and AItechnologies to provide advanced automation that increases productivity or enables new products. We forecast steady growth inspending over the medium term, but there is elevated downside ... Read More

  • Germany Pharmaceuticals & Healthcare Q1 2019

    ... over the coming years, delaying much-needed healthcare reformsand creating an uncertain market for drugmakers and healthcare providers. Nonetheless, as with many of its Western Europeanpeers, an ageing population and high per capita spending will ensure ... Read More

  • Ireland Pharmaceuticals & Healthcare Q1 2019

    Ireland Pharmaceuticals & Healthcare Q1 2019 Key View: 3G/4G To Drive Mobile Market Growth Read More

  • Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 424200

    ... save countless hours of research. Key Findings: Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors Industry (U.S.) to reach $1,395,222 million by 2025. Drugs (Pharmaceuticals) and Druggists' Merchandise Distributors Industry, including Average EBITDA, Operating Ratios and Sales ... Read More

  • Pharmacies and Drug Stores Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 446110

    ... hours of research. Key Findings: Pharmacies and Drug Stores Industry (U.S.) to reach $376,368 million by 2025. Pharmacies and Drug Stores Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: ... Read More

  • Bangladesh Pharmaceuticals & Healthcare Q1 2019

    ... will continue to dominate the market given low purchasingpower and the still underdeveloped health system. Meanwhile, domestic pharmaceutical firms will continue to develop theirmanufacturing capacity and expanding their global footprint, including an increase of their ... Read More

  • Belgium Pharmaceuticals & Healthcare Q1 2019

    ... environment is unlikely to see animmediate improvement to burdensome pricing and reimbursement regulation, key improvements - with respect to healthcareaccess, investment, and digital transformation - support the positive growth trajectory for Belgium's health andpharmaceutical sectors. Read More

  • Lebanon Pharmaceuticals & Healthcare Q1 2019

    ... include compulsory covers, will support significant short-term growth in terms of written premiums. In the smaller life segment, the outlook is more subdued, as low average income ratesrestrict capacity for savings and investments to a ... Read More

  • Czech Republic Pharmaceuticals & Healthcare Q1 2019

    ... Europe and the ongoing refugee crisis, continue to simmer.Cementing this expenditure growth will be the country's positive economic outlook, with Czech Republic among the most stableeconomies in emerging Europe. Expenditure will predominantly be directed at ... Read More

  • Kazakhstan Pharmaceuticals & Healthcare Q1 2019

    ... mining sector remains well placed for long-term expansion over the next few years, with the country takingadvantage of its geographical location to position itself as an important supplier of commodities to Asian and European markets. Read More

  • South Korea Pharmaceuticals & Healthcare Q1 2019

    ... refined fuels. The awarding of US waivers in November will allow South Korea to continue importingfrom Iran for 180 days, though political and operational considerations are likely to incentivise diversification to alternative suppliers.LNG imports will ... Read More

  • Costa Rica Pharmaceuticals & Healthcare Q1 2019

    ... manufacturers are unable to meet pharmaceutical demand, whichcontinues to be met through imports, and notably on the high-tech end of the scale. Well-developed healthcare infrastructure and avariety of elective services on offer have also contributed ... Read More

  • Iraq Pharmaceuticals & Healthcare Q1 2019

    ... treatment will support rising healthcarespending. Although the new government will look to increase spending on public service delivery and social welfare, structuralchallenges and low spending per capita on medicine will limit opportunities presented to drugmakers ... Read More

  • Israel Pharmaceuticals & Healthcare Q1 2019

    ... a thriving biotechnology start-up culture as well asmaking necessary funding, and regulatory adjustments for its five-year national digital health plan will future-proof Israel'stechnological infrastructure and ensure it remains above the majority of its regional peers. Read More

  • Panama Pharmaceuticals & Healthcare Q1 2019

    ... to weigh on the country’s ability to improve accessto healthcare in the short term. The small pharmaceutical market size by regional standards will limit commercial opportunitiespresented to drugmakers, although sustained market expansion will support rising ... Read More

  • Singapore Pharmaceuticals & Healthcare Q1 2019

    ... to treatment is relatively easy and the authorities arecommitted to healthcare outcome improvements, which will support volume and value growth of the market. Medicine sales will besupported by an ageing demographic and the high prevalence ... Read More

  • Denmark Pharmaceuticals & Healthcare Q1 2019

    ... to implement further medicine price controls. However,the country’s sizable and growing pensionable population will translate into a greater demand for high-value prescription drugs overthe long term, as the elderly consume more advanced treatments. This, along ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q1 2019

    ... through subsidised health insuranceschemes, and authorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground forsubstantial volume and value growth. On the other, this potential will mostly attract ... Read More

  • Greece Pharmaceuticals & Healthcare Q1 2019

    ... resulting in high levels of debt. Medicine sales will remain on a lowly growthtrajectory, albeit now positive, due to restrictive public funding. Repressive government policy, including aggressive pricing, highclawback and rebates, will continue to repress ... Read More

  • Romania Pharmaceuticals & Healthcare Q1 2019

    ... with a severe lack of public healthcarefinancing shifting the burden of costs onto patients. Having said this, pharmaceutical market growth remains on a robust trajectory,outperforming all EU member states, due to low levels of spending ... Read More

  • Angola Pharmaceuticals & Healthcare Q1 2019

    ... will be driven the country’s growing disease burden andincreasing population. However, given the low levels of affordability, poor access to healthcare, and relatively young age of itspopulation, the market will mainly be suited to generic ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog